Clinicians underutilize RSV testing in adults with respiratory or cardiac exacerbations, potentially obscuring the true burden of disease.

Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...

RSV hospitalization rates in older adults reached 58.3 per 100,000 in winter 2023-24, nearly half the rate of influenza at 114.6 per 100,000. Mortality and clinical outcomes were comparable between ...

Recovering from respiratory syncytial virus often doesn't end when it's time to leave the hospital, even for younger adults. Subscribe to our newsletter for the latest sci-tech news updates. For ...

"This study includes CDC’s first comprehensive estimates of RSV disease burden in U.S. adults, including hospitalizations and in-hospital deaths. It demonstrates that RSV caused a substantial burden ...

Respiratory syncytial virus (RSV) infections in older adults lead to significantly more severe health outcomes and long-term cardiovascular complications compared to other common causes of ...

Adults aged 80 and over, as well as all residents in care homes for older adults, will become eligible for the RSV vaccine ...

This week in JAMA Network Open, a team led by researchers from respiratory syncytial virus (RSV) vaccine-maker Pfizer ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged 60 and older, with approximately 75% effectiveness against RSV-associated ...

From early failures to prefusion F protein breakthroughs, RSV vaccine development has accelerated, reshaping prevention ...

Data shows that ER visits and hospital admissions for RSV have been climbing in New Jersey since early October. Currently, ER ...

All older adults over the age of 80 will now be eligible for the RSV vaccine. The RSV vaccine has been routinely available to ...